25
서 론
, , ,
2
[1]. 2001 NCEP-ATP III Panel
,
[2].
(nonalcoholic fatty liver disease,
NAFLD) , ,
[3].
[4].
NAFLD ,
1980
[5]. NAFLD
(simple steatosis)
, (non-
alcoholic steatohepatitis, NASH) ,
2 ,
[6-8].
,
NAFLD ,
3-24%[9], 29%
[10], 9-26%
NAFLD [11-12].
NAFLD , 2
,
[3]. NHANES III
, , ,
2
2 [9].
,
[13]
, [14]
NAFLD
.
(alanine aminotransferase;
SGPT) NAFLD NASH
NAFLD
90% [15].
SGPT
(aspartate aminotransferase;
SGOT)
대사증후군과 알라닌 아미노전이효소와의 관련성: 국민건강영양조사 제3기(2005년)
한미아 류소연 박종 강명근 김기순
조선대학교 의과대학 예방의학교실 조선대학교 내성세포연구센터
원 저
26
83% [16]. NAFLD
SGPT
[17].
Hispanic Health and Nutrition Examination Survey
2,999 20
SGPT (>43
IU/L) 4.1
[18]. SGOT SGPT 40 IU/L
1.2-4.23
2.88-3.20
[11].
NAFLD
[22] .
2005
(The Third Korea National Health and Nutrition
Examination Survey; KNHANES , 2005)
SGPT
NAFLD
.
대상 및 방법
1. 대상
2005
19
5,278
HBsAg , SGOT/SGPT 2
, SGOT SGPT 160 IU/L ,
,
40g , 20g
953 4,325
.
2. 방법
SGPT 40 IU/L SGPT
NCEP/ATP
III [2], -
. (
90 , 80 ), (
130/85 mmHg ),
( 150 mg/dL),
( < 40 mg/dL, < 50 mg/dL),
( 110 mg/dL )
3
.
, , , ,
, .
3. 자료분석
SPSS ver. 12.0 . SGPT
, .
19-44 , 45-64 , 65
.
, .
SGPT
,
SGPT .
p-value 0.05 .
연구성적
1. 성에 따른 대사증후군과 SGPT 증가와의 관련성
27.9%(242
), 26.6%(84 ) , SGPT
13.7%(242 ), 3.3%(84 ) .
SGPT ,
SGPT 9.0%
26.0% , ,
, ,
SGPT
.
SGPT 2.0%, 6.8%
, , ,
, ,
SGPT
27
(Table 1).
, , , ,
SGPT .
4.60(95% CI=3.40-6.23)
, , ,
,
Men(N=1,764) Women(N=2,561)
Total Elevated SGPT Total Elevated SGPT
Metabolic syndrome
No 1,271(72.1) 114( 9.0)*
1,880(73.4) 38(2.0)*
Yes 493(27.9) 128(26.0) 681(26.6) 46(6.8)
Abdominal obesity
No 1,291(73.2) 121( 9.4)*
1,474(57.6) 20(1.4)*
Yes 473(26.8) 121(25.6) 1,087(42.4) 64(5.9)
High blood pressure
No 976(55.3) 106(10.9)*
1,803(70.4) 45(2.5)*
Yes 788(44.7) 136(17.3) 758(29.6) 39(5.1)
High triglyceride
No 1,106(62.7) 79( 7.1)*
2,009(78.4) 51(2.5)*
Yes 658(37.3) 163(24.8) 552(21.6) 33(6.0)
Low HDL-cholesterol
No 926(52.5) 93(10.0)*
913(35.7) 22(2.4)*
Yes 838(47.5) 149(17.8) 1,648(64.3) 62(3.8)
High blood glucose
No 1,508(85.5) 197(13.1) 2,308(90.1) 64(2.8)*
Yes 256(14.5) 45(17.6) 253( 9.9) 20(7.9)
Values are expressed as frequency(%)
* p<0.05
Table Table Table Table 1. 1. 1. 1. Association between the metabolic syndrome and the elevated alanine aminotransferase level by sex
Men(N=1,764) Women(N=2,561)
Crude OR
(95% C.I.)
Adjusted OR
(95% C.I.)
Crude OR
(95% C.I.)
Adjusted OR
(95% C.I.)
Metabolic syndrome 3.55(2.69-4.70) 4.60(3.40-6.23) 3.51(2.26-5.44) 3.49(2.07-5.90)
Abdominal obesity 3.32(2.51-4.39) 3.94(2.94-5.29) 4.54(2.73-7.56) 4.33(2.49-7.51)
High blood pressure 1.71(1.30-2.25) 2.30(1.71-3.10) 2.11(1.36-3.28) 1.73(1.01-2.98)
High triglyceride 4.28(3.20-5.71) 4.32(3.20-5.83) 2.44(1.55-3.82) 2.13(1.33-3.41)
Low HDL-cholesterol 1.93(1.46-2.55) 1.95(1.47-2.59) 1.58(0.96-2.59) 1.45(0.88-2.40)
High blood glucose 1.41(0.99-2.02) 1.88(1.28-2.76) 3.01(1.79-5.06) 2.39(1.36-4.18)
OR, odds ratio; C.I., confidence interval.
Adjusted for age(continuous variable), marital status(single, with spouse, widowed divorced separated), education status( elementary
school, middle school, high school, college), health insurance(community health insurance, employer-provided health insurance, medical aid,
uninsured), smoking(nonsmoker, current smoker) and exercise(none, regular).
Table Table Table Table 2. 2. 2. 2. Odds ratios for the elevated alanine aminotransferase level according to presence of the metabolic syndrome by sex
28
.
3.49(95% CI=2.07-5.90)
, ,
,
(Table 2).
2. 연령에 따른 대사증후군과 SGPT 증가와의
관련성
19-44 12.4%,
45-64 36.5%, 65 49.6% , SGPT
19-44 8.0%(165 ), 45-64 8.0%(124 ),
65 5.2%(37 ) . SGPT
, 19-44
SGPT 5.5%
25.8% , ,
, , ,
SGPT
. 45-64
SGPT 4.4%
14.3% ,
, , ,
SGPT
. 65
SGPT 2.8%
7.7% ,
,
SGPT (Table 3).
, , , ,
SGPT
. 19-44
4.57
(95% CI=3.13-6.67) ,
, ,
. 45-64
3.92(95% CI=2.64-5.82)
Age 19-44 years (N=2,065) Age 45-64 years (N=1,555) Age 65 years (N=705)
Total Elevated SGPT Total Elevated SGPT Total Elevated SGPT
Metabolic syndrome
No 1,809(87.6) 99( 5.5)*
987(63.5) 43( 4.4)*
355(50.4) 10( 2.8)*
Yes 256(12.4) 66(25.8) 568(36.5) 81(14.3) 350(49.6) 27( 7.7)
Abdominal obesity
No 1,586(76.8) 83( 5.2)*
840(54.0) 42( 5.0)*
339(48.1) 16( 4.7)
Yes 479(23.2) 82(17.1) 715(46.0) 82(11.5) 366(51.9) 21( 5.7)
High blood pressure
No 1,746(84.6) 103( 5.9)*
822(52.9) 41( 5.0)*
211(29.9) 7( 3.3)
Yes 319(15.4) 62(19.4) 733(47.1) 83(11.3) 494(70.1) 30( 6.1)
High triglyceride
No 1,629(78.9) 65( 4.0)*
1,007(64.8) 47( 4.7)*
479(67.9) 18( 3.8)*
Yes 436(21.1) 100(22.9) 548(35.2) 77(14.1) 226(32.1) 19( 8.4)
Low HDL-cholesterol
No 967(46.8) 61( 6.3)*
619(39.8) 45( 7.3) 253(35.9) 9( 3.6)
Yes 1,098(53.2) 104( 9.5) 936(60.2) 79( 8.4) 452(64.1) 28( 6.2)
High blood glucose
No 1,987(96.2) 153( 7.7)*
1,291(83.0) 88( 6.8)*
538(76.3) 20( 3.7)*
Yes 78( 3.8) 12(15.4) 264(17.0) 36(13.6) 167(23.7) 17(10.2)
Values are expressed as frequency(%)
* p<0.05
Table Table Table Table 3. 3. 3. 3. Association between the characteristics of the study population and the elevated alanine aminotransferase level by age
29
, ,
,
. 65
3.43
(95% CI=1.59-7.42)
,
(Table 4).
고 찰
NAFLD
, , ,
, Mallory
[19], ,
, , ,
[20].
NAFLD
NAFLD
NAFLD
[12].
,
.
.
.
[21].
( , , ,
, )
[23].
SGPT ( , ,
)
[24].
NAFLD
SGPT NAFLD
[9,17,25-27].
SGPT
, HBsAg , SGOT/SGPT
2 , SGOT SGPT 160 IU/L
Age 19-44 years (N=2,065) Age 45-64 years (N=1,555) Age 65 years (N=705)
Crude OR
(95% C.I.)
Adjusted OR
(95% C.I.)
Crude OR
(95% C.I.)
Adjusted OR
(95% C.I.)
Crude OR
(95% C.I.)
Adjusted OR
(95% C.I.)
Metabolic syndrome 6.00(4.24-8.47) 4.57(3.13-6.67) 3.65(2.48-5.37) 3.92(2.64-5.82) 2.88(1.37-6.05) 3.43(1.59-7.42)
Abdominal obesity 3.74(2.70-5.17) 5.16(3.58-7.44) 2.46(1.67-3.62) 3.69(2.44-5.58) 1.22(0.63-2.39) 1.46(0.71-3.02)
High blood pressure 3.84(2.73-5.41) 2.03(1.41-2.92) 2.43(1.65-3.58) 2.16(1.45-3.22) 1.88(0.81-4.36) 1.92(0.81-4.51)
High triglyceride 7.16(5.12-9.99) 4.60(3.20-6.61) 3.33(2.28-4.87) 2.98(2.02-4.40) 2.35(1.20-4.57) 2.39(1.21-4.70)
Low HDL-cholesterol 1.55(1.11-2.15) 2.14(1.51-3.04) 1.17(0.80-1.72) 1.42(0.96-2.11) 1.79(0.83-3.85) 2.23(0.99-5.02)
High blood glucose 2.17(1.15-4.12) 1.51(0.76-3.00) 2.15(1.42-3.26) 1.85(1.21-2.83) 2.93(1.50-5.74) 2.79(1.41-5.52)
OR, odds ratio; C.I., confidence interval.
Adjusted for age(continuous variable), marital status(single, with spouse, widowed divorced separated), education status( elementary school,
middle school, high school, college), health insurance(community health insurance, employer-provided health insurance, medical aid,
uninsured), smoking(nonsmoker, current smoker) and exercise(none, regular).
Table Table Table Table 4. 4. 4. 4. Odds ratios for the elevated alanine aminotransferase level according to presence of the metabolic syndrome by age
30
, ,
. SGOT/SGPT 2 90%
[28], NAFLD 4
(160 IU/L)
[29,30]. SGPT
5
SGPT .
SGPT
, ,
.
Tsai 22
SGPT( 41U/L,
31U/L)
, , ,
[17].
[28]
, , ,
, ,
SGPT ( 40 U/L)
SGPT
.
SGPT
, [29].
SGPT NAFLD
.
SGPT
.
SGPT
. NAFLD
SGPT
.
NAFLD SGPT
,
.
,
, ,
, NAFLD
.
SGPT
. SGPT
NAFLD
,
.
참고문헌
1. Reaven GM. Role of insulin resistance in human
disease. Diabetes 1988; 37: 1595-607
2. Expert panel on detection, evaluation, and treatment
of high blood cholesterol in adults: executive
summary of the third report of the national
cholesterol education program (NCEP) expert
panel on detection, evaluation, and treatment of
high blood cholesterol in adults (adult treatment
panel III). JAMA 2001; 285: 2486-97
3. Marchesini G, Brizi M, Bianchi G, Tomassetti S,
Bugianesi E, Lenzi M, et al. Nonalcoholic fatty
liver disease: a feature of the metabolic syndome.
Diabetes 2001; 50: 1844-50
4. Kim JM, Park JY, Nam HK, Kim JW, Park SK,
Nam KJ et al. Prevalence of metabolic syndrome
in type 2 DM patients with non-alcoholic fatty
liver. J Korean Diabetes Assoc 2006; 30(6): 442-
31
449 (Korean)
5. Angulo P. Nonalcoholic fatty liver disease. N Engl
J Med 2002; 346: 1221-1231
6. Wanless IR, Lentz JS. Fatty liver hepatitis(steatoh-
epatitis) and obesity: an autopsy study with
analysis of risk factors. Hepatology 1990; 12(5):
1106-1110
7. Dixon JB, Bhathal PS, O’Brien PE. Nonalcoholic
fatty liver disease: predictors of nonalcoholic
steatohepatitis and liver fibrosis in the severly
obese. Gastroenterology 2001; 121(1): 91-100
8. Yu AS, Keeffe EB. Nonalcoholic fatty liver
disease. Rev Gastroenterol Disord 2002; 2: 11-9
9. Clark JM, Brancati FL, Diehl AM. Nonalcoholic
fatty liver disease. Gastroenterology 2002; 122:
1649-1657
10. Jimba S, Nakagami T, Takahashi M, Wakamatsu
T, Hirota Y, Iwamoto Y, et al. Prevalence of
non-alcoholic fatty liver disease and its association
with impaired glucose metabolism in Japanese
adults. Diabet Med 2005; 22: 1141-1145
11. Park SH, Kim BI, Yoo TW, Kim JW, Cho YK,
Sung IK, Park CY, et al. Nonalcoholic fatty liver
disease and abnormal liver function test in the
heSGPTh screen examinees: the relationship with
insulin resistance. Korean J Gastroenterol 2003;
41: 366-373 (Korean)
12. Oh SY, Cho YK, Kang MS, Yoo TW, Park JH,
Kim HJ, et al. The association between increased
alanine aminoransaminase activity and metabolic
factors in nonalcoholic fatty liver disease. Metabo-
lism 2006; 55: 1604-1609
13. Moon KW, Leem JM, Bae SS, Lee KM, Kim SH,
Chae HB, et al. The prevalence of metabolic
syndrome in patients with nonalcoholic fatty liver
disease. Korean J Hepatol 2004; 10: 197-206 (Korean)
14. Kim SM, Kim JA, Han JH, Cho KH, Yoon DK.
Nonalcoholic fatty liver disease and metabolic
syndrome in nonobese, nondiabetic adults. Korean
J Obese 2006; 15(1): 44-51 (Korean)
15. Daniel S, Ben-Menachem T, Vasudevan G, Ma
CK, Blumenkehl M. Prospective evaluation of
unexplained chronic liver transaminase abnormal-
ities in asymptomatic and symptomatic patients.
Am J Gastroenterol 1999; 94: 3010-3014
16. Pratt DS, Kaplan MM. Evaluation of abnormal
liver enzyme results in asymptomatic patients. N
Engl J Med 2000; 342: 1266-1271
17. Tsai PY, Yen CJ, Li YC, Chiu TY, Chen CY, Jan
CF. Association between abnormal liver function
and risk factors for metabolic syndrome among
freshmen. J Adolesc Health 2007; 41: 132-137
18. Meltzer AA, Everhart JE. Association between
diabetes and elevated serum alanine aminorans-
aminase activity among Mexican Americans. Am
J Epidemiol 1997; 146: 565-571
19. Ludwig J, Viggiano TR, McGill DB, Oh BJ.
Nonalcoholic steatohepatitis: Mayo Clinic experie-
nces with a hitherto unnamed disease. Mayo Clin
Proc 1980; 55: 434-438
20. . .
2006; 0: 203-215
21. . .
2006; 7(2): 120-123
22. Yeon JE. Nonalcoholic fatty Liver disease: patho-
genesis and treatment. Korean J Med 2006; 70(3):
246-252 (Korean)
23. . .
2005; 0: 327-336
24. Green RM, Flamm S. AGA technical review on
the evaluation of liver chemistry tests. Gastroente-
rology 2002; 123: 1367-1384
25. Brunt EM. Nonalcoholic steatohepatitis. Semin
Liver Dis 2004; 24: 3-20
26. Ruhl CE, Everhart JE. Determinants of the assoc-
iation of overweight with elevated serum alanine
aminoransaminase activity in the United States.
Gastroenterology 2003; 124: 71-79
27. Nam SM, Yu HY, Lee MY, Koh JH, Shin JY, Shin
YG, et al. Alcohol consumption, liver enzymes,
and prevalence of metabolic syndrome in Korean
aults men. J Korean Diabetes Assoc 2007; 31(3):
32
253-260 (Korean)
28. Cohen JA, Kaplan MM. The SGOT/SGPT ratio-an
indicator of alcohol liver disease. Dig Dis Sci
1979; 24: 385-838
29. Bacon BR, Farahvash MJ, Janney CG, Neuschw-
ander-Tetri BA. Nonalcoholic steatohepatitis: an
expanded clinical entity. Gastroenterology 1994;
107: 1103-1109
30. Diehl AM, Goodman Z, Ishak KG. Alcoholic liver
disease in nonalcoholics: a clinical and histologic
comparison with alcohol-induced liver injury.
Gastroenterology 1988; 95: 1056-1062
31. Park HS, Han JH, Choi KM, Kim SM. Relation
between elevated serum alanine aminoransaminase
and metabolic syndrome in Korean adolescents.
Am J Clin Nutr 2005; 82: 1046-1051
32. Choi KM, Lee KW, Kim HY, Seo JA, Kim SG,
Kim NH, et al. Association among serum ferritin,
alanine aminotransferase levels, and metabolic
syndrome in Korean postmenopausal women.
Metabolism 2005; 54: 1510-1514
33
Purpose: The aim of this study was to investigate the association between the metabolic syndrome and alanine
aminotransferase(SGPT) levels in Korean adults.
Methods: The study subjects were 4,325 adults aged 19 years without an apparent cause of liver disease from
the Third Korea National Health and Nutrition Examination Survey(2005). The metabolic syndrome was defined using
criteria established by the NCEP/ATP III, while abdominal obesity was assessed based on the Asia-Pacific guidelines.
Subjects with SGPT 40 IU/L were considered to have elevated SGPT levels. Demographic characteristics, waist
circumference, blood pressure, triglyceride, HDL cholesterol, fasting blood sugar were recorded for statistical analysis.
Results: The prevalence of elevated SGPT levels was significantly increase with the presence of the metabolic
syndrome and its components. In multiple logistic regression analyses, odds ratio for the elevated SGPT levels was
significantly high in the subjects with the metabolic syndrome compared to the subjects without metabolic syndrome
after adjusted for socio-demographic characteristics and health-related behavior.
Conclusions: The metabolic syndrome was independently associated with SGPT levels in Korean adults.
: Metabolic Syndrome X, Alanine Aminotransferase(SGPT)
Metabolic Syndrome and Serum Alanine Aminotransferase Levels in Korean Adults : The
Third Korea National Health and Nutrition Examination Survey (KNHANES ), 2005
Mi Ah Han1),2)
, So Yeon Ryu1),2)
, Jong Park1),2)
, Myung Geun Kang1), Ki Soon Kim
1)